|
1
|
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
|
Int J Geriatr Psychiatry
|
2001
|
3.09
|
|
2
|
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
|
Neurology
|
2006
|
2.21
|
|
3
|
Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.
|
Neurology
|
2000
|
2.10
|
|
4
|
Minimum Data Set Plus (MDS+) scores compared with scores from five rating scales.
|
J Am Geriatr Soc
|
1996
|
1.27
|
|
5
|
A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer's disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer's Disease Cooperative Study.
|
Alzheimer Dis Assoc Disord
|
1997
|
1.05
|
|
6
|
Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
|
J Nutr Health Aging
|
2012
|
1.00
|
|
7
|
Measures of psychiatric symptoms in Alzheimer patients: a review.
|
Alzheimer Dis Assoc Disord
|
1996
|
0.89
|
|
8
|
A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.
|
Neurology
|
2001
|
0.84
|
|
9
|
Carbamazepine-induced tics.
|
Clin Neuropharmacol
|
1989
|
0.84
|
|
10
|
Scopolamine challenges in Alzheimer's disease.
|
Psychopharmacology (Berl)
|
1985
|
0.82
|
|
11
|
Function of the adrenal cortex in patients with major depression.
|
Psychiatry Res
|
1987
|
0.76
|
|
12
|
Editorial: Collaborative Efforts to Prevent Alzheimer's Disease.
|
J Nutr Health Aging
|
2017
|
0.75
|
|
13
|
Alzheimer's disease. How memory fails: a theoretical model.
|
Geriatr Nurs
|
1985
|
0.75
|
|
14
|
Alzheimer's disease in long-term care: maximizing treatment options.
|
J Am Med Dir Assoc
|
2003
|
0.75
|
|
15
|
EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
|
J Prev Alzheimers Dis
|
2017
|
0.75
|